Immuneering Statistics

Total Valuation

Immuneering has a market cap or net worth of $57.96 million. The enterprise value is $26.87 million.

Market Cap	57.96M
Enterprise Value	26.87M

Important Dates

The last earnings date was Thursday, March 20, 2025, after market close.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Immuneering has 35.89 million shares outstanding. The number of shares has increased by 5.51% in one year.

Current Share Class	35.89M
Shares Outstanding	35.89M
Shares Change (YoY)	+5.51%
Shares Change (QoQ)	+4.05%
Owned by Insiders (%)	24.11%
Owned by Institutions (%)	11.98%
Float	27.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.23
P/TBV Ratio	1.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.10.

Current Ratio	5.28
Quick Ratio	4.82
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -92.51% and return on invested capital (ROIC) is -56.97%.

Return on Equity (ROE)	-92.51%
Return on Assets (ROA)	-51.57%
Return on Invested Capital (ROIC)	-56.97%
Return on Capital Employed (ROCE)	-141.72%
Revenue Per Employee	n/a
Profits Per Employee	-$897,597
Employee Count	68
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.60% in the last 52 weeks. The beta is -0.30, so Immuneering's price volatility has been lower than the market average.

Beta (5Y)	-0.30
52-Week Price Change	-43.60%
50-Day Moving Average	1.76
200-Day Moving Average	1.76
Relative Strength Index (RSI)	46.15
Average Volume (20 Days)	165,487

Short Selling Information

The latest short interest is 1.42 million, so 3.96% of the outstanding shares have been sold short.

Short Interest	1.42M
Short Previous Month	1.63M
Short % of Shares Out	3.96%
Short % of Float	5.22%
Short Ratio (days to cover)	6.74

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-64.07M
Pretax Income	-56.07M
Net Income	-61.04M
EBITDA	-63.69M
EBIT	-64.07M
Earnings Per Share (EPS)	-$2.04

Full Income Statement

Balance Sheet

The company has $36.14 million in cash and $4.16 million in debt, giving a net cash position of $31.98 million or $0.89 per share.

Cash & Cash Equivalents	36.14M
Total Debt	4.16M
Net Cash	31.98M
Net Cash Per Share	$0.89
Equity (Book Value)	41.39M
Book Value Per Share	1.33
Working Capital	32.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$55.00 million and capital expenditures -$84,875, giving a free cash flow of -$55.08 million.

Operating Cash Flow	-55.00M
Capital Expenditures	-84,875
Free Cash Flow	-55.08M
FCF Per Share	-$1.53

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immuneering does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.51%
Shareholder Yield	n/a
Earnings Yield	-103.71%
FCF Yield	-93.59%

Analyst Forecast

The average price target for Immuneering is $11.00, which is 581.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.00
Price Target Difference	581.12%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1